ERTAPENEM Drug Patent Profile
✉ Email this page to a colleague
When do Ertapenem patents expire, and when can generic versions of Ertapenem launch?
Ertapenem is a drug marketed by Acs Dobfar Spa, Eugia Pharma, Gland, Qilu Antibiotics, Savior Lifetec Corp, and Sun Pharm. and is included in six NDAs.
The generic ingredient in ERTAPENEM is ertapenem sodium. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ertapenem
A generic version of ERTAPENEM was approved as ertapenem sodium by ACS DOBFAR SPA on April 16th, 2018.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ERTAPENEM?
- What are the global sales for ERTAPENEM?
- What is Average Wholesale Price for ERTAPENEM?
Summary for ERTAPENEM
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Prices: | Drug price information for ERTAPENEM |
| What excipients (inactive ingredients) are in ERTAPENEM? | ERTAPENEM excipients list |
| DailyMed Link: | ERTAPENEM at DailyMed |
US Patents and Regulatory Information for ERTAPENEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acs Dobfar Spa | ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 208790-001 | Apr 16, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Qilu Antibiotics | ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 218067-001 | Oct 31, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Eugia Pharma | ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 209133-001 | Jun 25, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Gland | ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 212040-001 | Mar 26, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 209145-001 | May 2, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Savior Lifetec Corp | ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 207647-001 | Mar 19, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
